1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(2-methyl-4,5-dihydro-2H-imidazo[2',1':2,3]thiazolo[4,5-e]isoindol-8-yl)phenyl)urea

ID: ALA5206333

PubChem CID: 168295642

Max Phase: Preclinical

Molecular Formula: C26H26N6O2S

Molecular Weight: 486.60

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  Cn1cc2c(c1)-c1c(sc3nc(-c4ccc(NC(=O)Nc5cc(C(C)(C)C)on5)cc4)cn13)CC2

Standard InChI:  InChI=1S/C26H26N6O2S/c1-26(2,3)21-11-22(30-34-21)29-24(33)27-17-8-5-15(6-9-17)19-14-32-23-18-13-31(4)12-16(18)7-10-20(23)35-25(32)28-19/h5-6,8-9,11-14H,7,10H2,1-4H3,(H2,27,29,30,33)

Standard InChI Key:  NQRQJUYGBOBQOV-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 35 40  0  0  0  0  0  0  0  0999 V2000
   -2.3200   -2.9941    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6056   -2.5815    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8911   -2.9941    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8911   -3.8191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6056   -4.2316    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3200   -3.8191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1065   -4.0741    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3783   -3.4067    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1065   -2.7392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2031   -3.4067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7771   -1.7747    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5975   -1.6884    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9330   -2.4420    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7689   -0.8816    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0544   -0.4691    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4415   -1.0211    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0544    0.3555    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7686    0.7681    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7678    1.5904    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0534    2.0029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3419    1.5939    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3371    0.7696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0534    2.8276    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3392    3.2400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6249    2.8276    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3392    4.0648    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0893    3.2400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1754    4.0598    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9818    4.2312    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.3940    3.5173    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8423    2.9047    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2187    3.5173    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6311    4.2316    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2187    2.6911    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9330    3.1049    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  3  2  1  0
  4  3  1  0
  5  4  1  0
  6  5  1  0
  1  6  1  0
  4  7  2  0
  8  7  1  0
  9  8  1  0
  3  9  2  0
  8 10  1  0
  2 11  1  0
 12 11  1  0
 13 12  1  0
  1 13  1  0
 12 14  2  0
 14 15  1  0
 15 16  2  0
 11 16  1  0
 17 15  1  0
 18 17  2  0
 19 18  1  0
 20 19  2  0
 21 20  1  0
 22 21  2  0
 17 22  1  0
 20 23  1  0
 23 24  1  0
 24 25  1  0
 24 26  2  0
 25 27  1  0
 28 27  2  0
 28 29  1  0
 29 30  1  0
 30 31  2  0
 31 27  1  0
 30 32  1  0
 32 33  1  0
 32 34  1  0
 32 35  1  0
M  END

Alternative Forms

  1. Parent:

    ALA5206333

    ---

Associated Targets(Human)

MOLT-4 (49676 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HL-60 (67320 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KG-1 (867 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MOLM-13 (2241 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MV4-11 (7307 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KG-1a (249 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NOMO-1 (191 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OCI-AML2 (350 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
THP-1 (11052 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562 (73714 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCL-22 (265 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FLT3 Tclin Tyrosine-protein kinase receptor FLT3 (13481 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 486.60Molecular Weight (Monoisotopic): 486.1838AlogP: 6.10#Rotatable Bonds: 3
Polar Surface Area: 89.39Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 8.27CX Basic pKa: 3.85CX LogP: 5.96CX LogD: 5.91
Aromatic Rings: 5Heavy Atoms: 35QED Weighted: 0.32Np Likeness Score: -1.67

References

1. Cilibrasi V, Spanò V, Bortolozzi R, Barreca M, Raimondi MV, Rocca R, Maruca A, Montalbano A, Alcaro S, Ronca R, Viola G, Barraja P..  (2022)  Synthesis of 2H-Imidazo[2',1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3/ITD mutations.,  235  [PMID:35339838] [10.1016/j.ejmech.2022.114292]

Source